Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery

Cerqueira, Rute; Correia, Manuel R.; Vilar, Hélder; Manso, Maria Conceição

doi:10.1007/s11695-017-2915-z

Cited by 5 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients underwent preoperative upper endoscopy (UE) after 20 days proton pump inhibitors (PPIs) or H2 blockers off, with Helicobacter Pylori (HP) test. When present, HP was eradicated according to Maastricht consensus [8].…”

Section: Preoperative Evaluationmentioning

confidence: 99%

Does antrum size matter in sleeve gastrectomy? A prospective randomized study

Pizza¹,

D’Antonio²,

Lucido

et al. 2020

Surg Endosc

View full text Add to dashboard Cite

Background Laparoscopic sleeve gastrectomy (LSG) is a safe and effective bariatric procedure in terms of excess weight loss. Nevertheless, controversies still exist on several technical and operative aspects of LSG. The aim of this study is to evaluate variations in anthropometric features in subjects with a LSG gastric resection starting from 2 cm or 6 cm from the pylorus. Secondary aim was the evaluation of differences in morbidity, food tolerance, and GERD incidence studied with upper endoscopy (UE) and GERD Health-Related Quality-of-Life score. Methods Patients were prospectively randomized into 2 groups: Group A (at 2 cm proximally to the pylorus) and Group B (at 6 cm proximally to the pylorus). All patients were followed-up at 3, 6, 12, and 24 months. UE was performed in all patients at 12 or 24 months. Results One hundred and fifty met the inclusion criteria and were enrolled in the study. The anthropometric features (BMI,

show abstract

Section: Preoperative Evaluationmentioning

confidence: 99%

Does antrum size matter in sleeve gastrectomy? A prospective randomized study

Pizza¹,

D’Antonio²,

Lucido

et al. 2020

Surg Endosc

View full text Add to dashboard Cite

show abstract

“…A total of 279 citations were present on PubMed . Following the title and abstracts review, a total of 24 studies meet inclusion criteria [7–30], whereas the others were ultimately excluded for different reasons (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review

Francesco

Zullo

Manta³

et al. 2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Cure rate following standard first-line regimens for Helicobacter pylori eradication is decreasing so several patients require two or more treatments. Antibiotic susceptibility-based therapy, advised in current guidelines, is largely impracticable in clinical practice. Some 'standard' regimens (triple therapies based on either levofloxacin or rifabutin, bismuth-based quadruple therapies, sequential, concomitant and hybrid therapies) were empirically used as rescue therapies. We performed a systematic review on recent studies carried out in European countries dealing with these regimens. A total of 24 studies, with 3804 patients, were identified. As second-line therapy, Pylera (89.2%) and sequential therapy (92.5%) achieved significantly higher cure rates as compared to all the other regimens. As third-line therapy, levofloxacin-based therapy (84.1%) and Pylera (83.6%) achieved similarly high cure rates, whereas standard, bismuth-based quadruple therapy (64.1%) achieved the lowest. As a rescue therapy, the success rate was close to 75% following all therapies used, with data on rifabutin-based regimen consolidated in the larger sample size. Overall, levofloxacin-amoxicillin triple therapy achieved higher eradication rates when the 14-rather than 10-day regimen was used (87.1 vs. 72.2%; P = 0.003). Among bismuth-based therapies, Pylera achieved a significantly higher eradication rate than standard quadruple therapy (88 vs. 67%; P < 0.0001). These data suggest that a wise 'therapeutic package' following first-line therapy could be Pylera, levofloxacin-and rifabutin-based therapy, as long as Pylera therapy was not used as a first-line regimen and levofloxacin-based regimen was administered for 14 days. Eur J Gastroenterol Hepatol 33: e66-e70

show abstract

“…25 Por otro lado, hay autores como Pellicano 27 que plantean que la tasa de erradicación es similar con base en un estudio realizado por Cerqueira y col., prospectivo, observacional, donde los pacientes obesos pre-cirugía bariátrica alcanzaron tasas de erradicación comparable a no obesos luego de 2 regímenes de 1 a y 2 a línea de tratamiento de acuerdo con lo sugerido por el Consenso de Maastricht IV. 28 Pero este estudio adolece de un grupo de pacientes con IMC normal. Para Pellicano, el problema es la resistencia a los antibióticos y esta no es distinta en pacientes con IMC normal.…”

Section: Discussionunclassified

Erradicación del Helicobacter pylori en pacientes obesos pre-cirugía bariátrica

Laudanno¹,

Ahumaran²,

Thome³

et al. 2020

Acta gastroenterol. latinoam.

View full text Add to dashboard Cite

Many bariatric surgeons recommend routine Helicobacter pylori (H. pylori) screening as a part of the workup for bariatric surgery. Some studies suggested that obese patients have a lower eradication rate and the Body Mass Index could be independent risk factor for this failure. Objective. To evaluate the H. pylori eradication of a 14 days Quadruple Concomitant therapy in obese patients undergoing bariatric surgery compared against a control group. Material and Methods. Prospective study included 76 patients undergoing bariatric surgery and 75 control patients with a normal BMI and dyspepsia. Results. In the obese group, the eradication rate was 69% whereas in the control group was 89%. p < 0.05, Odds ratio 3.18 (CI 1.35-7.45). The distribution of age, gender, smoking and diabetes did not differ significantly between the two groups. Conclusions. Obese patients showed a significantly lower eradication of H. pylori than controls to a two weeks Quadruple Concomitant therapy.

show abstract

Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery

Cited by 5 publications

References 21 publications

Does antrum size matter in sleeve gastrectomy? A prospective randomized study

Does antrum size matter in sleeve gastrectomy? A prospective randomized study

Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review

Erradicación del Helicobacter pylori en pacientes obesos pre-cirugía bariátrica

Contact Info

Product

Resources

About